The importance of histological patterns on PD-L1 staining heterogeneity: Should we use pattern-based approach for selecting tumor samples for PD-L1 testing in lung adenocarcinomas?

Background/aim: Programmed death ligand-1 (PD-L1) is a predictive marker for immunotherapeutic agents. However, heterogeneous staining of PD-L1 can cause false-negative results. The aim of this study is to evaluate the importance of histological patterns on PD-L1 staining heterogeneity in lung adenocarcinomas (LAC). Materials and methods: PD-L1 immunohistochemistry (IHC) stain was performed to two different tissue cores of 128 LAC cases, and cut-off values are given for grouping the cases according to the percentage of staining (1%-10%, 11%-49%, 50%-100%). Staining rates between cores were compared and analyzed by their histological patterns. Also, the relation of the PD-L1 expression with the clinicopathological characteristics of the cases was analyzed. Results: Overall, PD-L1 expression was observed in 53 of 128 cases (41.4%, 1% cut-off), 23.5% of them were positive at 10% cut-off and 14.1% at 50% cut-off. PD-L1 expression was significantly related to the high grade micropapillary and solid patterns of adenocarcinomas (p:0.01). Staining cut-offs were mostly similar between cores (43/50, 86%) (k:0.843). However, 14% of them were positive only in one core (7 of 50). This false negativity was mostly related to the histological patterns. Conclusion: Our data reveal the heterogeneous staining of PD-L1 expression, also micropapillary and solid patterns show higher rates of PDL expression. Therewithal, these findings also highlight the importance of taking into consideration of histological patterns, when choosing a paraffin block for the PDL1.Key words: PD-L1, lung cancer, immunotherapy, lung adenocarcinoma

PDF

___

1. Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013; 499: 214-218. doi: org/10.1038/nature12213
2. Gridelli C, Rossi A, Carbone DP, Guarize J, Karachaliou N et al. Non-small-cell lung cancer. Nature Reviews Disease Primers 2015; 1 (15009). doi: org/10.1038/nrdp.2015.9
3. Miller KD, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR et al. Cancer treatment and survivorship statistics, 2019. A Cancer Journal for Clinicians 2019; 69: 363-385. doi: org/10.3322/caac.21565
4. Liu X, Wang P, Zhang C, Ma Z. Epidermal growth factor receptor (EGFR): A rising star in the era of precision medicine of lung cancer. Oncotarget 2017; 8 (30): 50209-50220. doi: 10.18632/oncotarget.16854
5. Chang L, Hui Y, Qianqian L, Haiquan C, Yuan L et al. Real World Experience of Crizotinib in 104 Patients With ALK Rearrangement Non-small-cell Lung Cancer in a Single Chinese Cancer Center. Frontiers Oncology 2019; 9: 1116. doi: 10.3389/fonc.2019.01116
6. Gubens MA, Davies M. NCCN Guidelines Updates: New ımmunotherapy strategies for ımproving outcomes in non-small cell lung cancer. The Journal of the National Comprehensive Cancer Network 2019; 17: 574-578. doi: org/10.6004/jnccn.2019.5005
7. Chen F, Zhuang X, Lin L, Yu P, Wang Y et al. New horizons in tumor microenvironment biology: challenges and opportunities. BMC Medical 2015; 13: 45. doi: 10.1186/ s12916-015-0278-7
8. Ohaegbulam KC, Assal A, Lazar-Molnar E, Yao Y, Zang X. Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends in Molecular Medicine 2015; 21 (1): 24-33. doi: org/10.1016/j.molmed.2014.10.009
9. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 29; 313(5795):1960-1964. doi: 10.1126/science.1129139
10. Okazaki T, Honjo T. PD-1 and PD-1 ligands: From discovery to clinical application. International Immunology 2007; 19: 813- 824. doi: org/10.1093/intimm/dxm057
11. Blank C, Mackensen A. Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: An update on implications for chronic infections and tumor evasion. Cancer Immunology Immunotherapy 2007; 56 (5): 739-745. doi: org/10.1007/ s00262-006-0272-1
12. Wang A, Wang HY, Liu Y, Zhao MC, Zhang HJ et al. The prognostic value of PD-L1 expression for non-small cell lung cancer patients: a meta-analysis. European Journal of Surgical Oncology 2015; 41: 450-456. doi: org/10.1016/j. ejso.2015.01.020
13. Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csöszi T et al. Pembrolizumab versus chemotherapy for PD-L1- positive non-small-cell lung cancer. The New England Journal of Medicine 2016; 375: 1823-1833. doi: org/10.1056/ NEJMoa1606774
14. Gagné A, Enlow W, Pigeon MA, Orain M, Turcotte S et al. Comprehensive assessment of PD-L1 staining heterogeneity in pulmonary adenocarcinomas using tissue microarrays. The American Journal of Surgical Pathology 2018; 42: 687-694. doi: org/10.1097/PAS.0000000000001013
15. Gradecki SE, Grange JS, Stelow EB. Concordance of PD-L1 expression between core biopsy and resection specimens of non-small cell lung cancer. The American Journal of Surgical Pathology 2018; 42: 1090-1094. doi: org/10.1097/ PAS.0000000000001085
16. Gagné A, Wang E, Bastien N, Orain M, Desmeules P et al. Impact of specimen characteristics on PD-L1 testing in non– small cell lung cancer: validation of the IASLC PD-L1 testing recommendations. Journal of Thoracic Oncology 2019; 14: 2062-2070. doi: org/10.1016/j.jtho.2019.08.2503
17. Hirsch FR, McElhinny A, Stanforth D, Ranger-Moore J, Jansson M et al. PD-L1 ımmunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project. Journal of Thoracic Oncology 2017; 12: 208-222. doi: org/10.1016/j.jtho.2016.11.2228
18. Ilie M, Long-Mira E, Bence C, Butori C, Lassalle S et al. Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies. Annals of Oncology 2016; 27: 147-153. doi: org/10.1093/annonc/mdv489
19. Rehman JA, Han G, Carvajal-Hausdorf DE, Wasserman BE, Pelekanou V et al. Quantitative and pathologist-read comparison of the heterogeneity of programmed deathligand 1 (PD-L1) expression in non-small cell lung cancer. Modern Pathology 2017; 30: 340-349. doi: org/10.1038/ modpathol.2016.186
20. Kitazono S, Fujiwara Y, Tsuta K, Utsumi H, Kanda S et al. Reliability of small biopsy samples compared with resected specimens for the determination of programmed death-ligand 1 expression in non-small-cell lung cancer. Clinical Lung Cancer 2015; 16: 385-390. doi: org/10.1016/j.cllc.2015.03.008
21. Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM et al. The 2015 World Health Organization classification of lung tumors: ımpact of genetic, clinical and radiologic advances since the 2004 classification. Journal of Thoracic Oncology 2015; 10:1243–1260. doi:org/10.1097/JTO.0000000000000630
22. Kadota K, Suzuki K, Kachala SS, Zabor EC, Sima CS et al. A grading system combining architectural features and mitotic count predicts recurrence in stage I lung adenocarcinoma. Modern Pathology 2012; 25(8): 1117-1127 doi: org/10.1038/ modpathol.2012.58
23. Chen Z, Li M, Ma K, Shang G, Liang J et al. Analysis of the clinicopathological characteristics, genetic phenotypes, and prognostic of pure mucinous adenocarcinoma. Cancer Medicine 2020; 9 (2): 517-529. doi: org/10.1002/cam4.2726
24. Scheel AH, Dietel M, Heukamp LC, Jöhrens K, Kirchner T et al. Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas. Modern Pathology 2016; 9 (2): 517-529. doi: 10.1002/cam4.2726
25. McHugh ML. Interrater reliability: The kappa statistic. Biochemica Medica 2012; 22: 276-282. doi: org/10.11613/ bm.2012.031
26. Jing W, Li M, Zhang Y, Teng F, Han A et al. PD-1/PD-l1 blockades in non-small-cell lung cancer therapy. OncoTargets and Therapy 2016; 9: 489-502. doi: org/10.2147/OTT.S94993
27. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and ıts ligands in tolerance and ımmunity. Annual Review of Immunology 2008; 26: 677-704. doi: org/10.1146/annurev. immunol.26.021607.090331
28. Philips GK, Atkins M. Therapeutic uses of anti-PD-1 and antiPD-L1 antibodies. International Immunology 2015; 27:39-46. doi: org/10.1093/intimm/dxu095
29. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. The New England Journal of Medicine 2012; 366:2443-2454. doi: org/10.1056/NEJMoa1200690
30. Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial. Lancet 2016; 387: 1540-1550. doi: org/10.1016/S0140-6736(15)01281-7
31. Casadevall D, Clavé S, Taus Á, Hardy-Werbin M, Rocha P et al. Heterogeneity of tumor and ımmune cell PD-L1 expression and lymphocyte counts in surgical NSCLC samples. Clinical Lung Cancer 2017; 18: 682-691.e5. doi: org/10.1016/j.cllc.2017.04.014
32. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger K et al. International Association for the study of lung cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma - an executive summary. Proceedings of the American Thoracic Society 2011; 8:381-385. doi: org/10.1513/ pats.201107-042ST
33. Motono N, Matsui T, Machida Y, Usuda K, Uramoto H. Prognostic significance of histologic subtype in p Stage I lung adenocarcinoma. Medical Oncology 2017; 34 (6): 100. doi: 10.1007/s12032-017-0962-x
34. Oki T, Aokage K, Nomura S, Tane K, Miyoshi T et al. Optimal method for measuring invasive size that predicts survival in invasive mucinous adenocarcinoma of the lung. Journal of Cancer Research and Clinical Oncology 2020. doi: org/10.1007/ s00432-020-03158-1
35. Munari E, Zamboni G, Lunardi G, Marchionni L, Marconi M et al. PD-L1 expression heterogeneity in non-small cell lung cancer: defining criteria for harmonization between biopsy specimens and whole sections. Journal of Thoracic Oncology 2018; 13: 1113-1120. doi: org/10.1016/j.jtho.2018.04.017
36. Gagné A, Wang E, Bastien N, Orain M, Desmeules P et al. Impact of specimen characteristics on PD-L1 testing in nonsmall cell lung cancer: validation of the IASLC PD-L1 testing recommendations. Journal of Thoracic Oncology 2019; 14:^2062-2070. doi: org/10.1016/j.jtho.2019.08.2503
37. Li H, Xu Y, Wan B, Song Y, Zhan P et al. The clinicopathological and prognostic significance of PD-L1 expression assessed by immunohistochemistry in lung cancer: A meta-analysis of 50 studies with 11,383 patients. Translational Lung Cancer Research 2019; 8: 429-449. doi: org/10.21037/tlcr.2019.08.04
38. Song P, Wu S, Zhang L, Zeng X, Wang J. Correlation between PD-L1 expression and clinicopathologic features in 404 patients with lung adenocarcinoma. Interdisciplinary Sciences, Computational Life Sciences 2019; doi: org/10.1007/s12539- 019-00329-8
39. Mandarano M, Bellezza G, Belladonna ML, Van den Eynde BJ, Chiari R et al. Assessment of TILs, IDO-1, and PD-L1 in resected non-small cell lung cancer: an immunohistochemical study with clinicopathological and prognostic implications. Virchows Archiv 2019; 474 (2): 159-168. doi: 10.1007/s00428- 018-2483-1
40. Driver BR, Miller RA, Miller T, Deavers M, Gorman B et al. Programmed death ligand-1 (pd-l1) expression in either tumor cells or tumor-infiltrating immune cells correlates with solid and high-grade lung adenocarcinomas. The Archives of Pathology & Laboratory Medicine 2017; 141 (11): 1529-1532. doi: org/10.5858/arpa.2017-0028-OA
41. Munari E, Zamboni G, Lunardi G, Marchionni L, Marconi M et al. PD-L1 expression heterogeneity in non–small cell lung cancer: defining criteria for harmonization between biopsy specimens and whole sections. Journal of Thoracic Oncology 2018; 13 (8): 1113-1120. doi: org/10.1016/j.jtho.2018.04.017
42. Haragan A, Field JK, Davies MPA, Escriu C, Gruver A et al. Heterogeneity of PD-L1 expression in non-small cell lung cancer: Implications for specimen sampling in predicting treatment response. Lung Cancer 2019; 134: 79-84. doi: 10.1016/j.lungcan.2019.06.005
43. Ng Kee Kwong F, Laggner U, McKinney O, Croud J, Rice A et al. Expression of PD-L1 correlates with pleomorphic morphology and histological patterns of non-small-cell lung carcinomas. Histopathology 2018; 72 (6): 1024-1032. doi: org/10.1111/ his.13466
44. Gagné A, Enlow W, Pigeon M-A, Orain M, Turcotte S et al. Comprehensive assessment of PD-L1 staining heterogeneity in pulmonary adenocarcinomas using tissue microarrays: ımpact of the architecture pattern and the number of cores. The American Journal of Surgical Pathology 2018; 42:687–694. doi: org/10.1097/PAS.0000000000001013
45. McLaughlin J, Han G, Schalper KA, Carvajal-Hausdorf D, Pelekanou V et al. Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer. JAMA Oncology 2016; 2: 46-54. doi: org/10.1001/ jamaoncol.2015.3638
46. Herbst RS, Baas P, Perez-Gracia JL, Felip E, Kim DW et al. Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: An updated analysis of keynote-010 trial. Annals of Oncology 2019; 1;30 (2): 281- 289. doi: 10.1093/annonc/mdy545.doi: org/10.1093/annonc/ mdy545